For the quarter ending 2026-03-31, TSHA had -$43,191K decrease in cash & cash equivalents over the period. -$40,902K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development license expense | - | 3,000 | - | - |
| Change in fair value of warrant liability | - | 736 | 292 | 171 |
| Net loss | -42,410 | -27,851 | -32,733 | -48,411 |
| Depreciation expense | 295 | 299 | 286 | 560 |
| Stock-based compensation | 5,547 | 3,529 | 3,285 | 6,484 |
| Non-cash change in fair value of term loan | 32 | 205 | 186 | 441 |
| Debt issuance costs expensed under the fair value option | - | 0 | 147 | - |
| Non-cash lease expense | 285 | 400 | 312 | 647 |
| Other | -27 | -32 | -28 | -236 |
| Prepaid expenses and other assets | 794 | 2,135 | -971 | 570 |
| Deferred revenue | - | -5,485 | 0 | -4,288 |
| Accounts payable | 1,289 | -2,126 | -1,948 | 3,921 |
| Accrued expenses and other liabilities | -5,149 | 2,674 | 5,008 | -1,393 |
| Net cash used in operating activities | -40,878 | -26,722 | -24,166 | -42,202 |
| Purchase of research and development license | 3,000 | - | - | - |
| Purchase of property, plant and equipment | 24 | 250 | 108 | 380 |
| Other | - | -3 | -60 | -71 |
| Net cash used in investing activities | -3,024 | -247 | -48 | -309 |
| Proceeds from issuance of common stock and pre-funded warrants from underwritten public offering, net of underwriting discounts and sales commissions and other offering costs | - | -70 | -454 | 216,170 |
| Proceeds from issuance of common stock pursuant to at-the-market offering, net of sales commissions and other offering costs | - | 48,435 | - | - |
| Prepayment of 2023 trinity term loan | - | 0 | 40,612 | - |
| Proceeds from 2025 trinity term loan, net | - | 0 | 49,853 | - |
| Payment of shelf registration costs | - | - | -14 | 47 |
| Proceeds from issuance of common stock upon exercise of warrants | - | 225 | - | - |
| Proceeds from common stock issuances under espp | 176 | 0 | 84 | 75 |
| Proceeds from stock option exercises | 516 | 1,023 | 197 | - |
| Other | 19 | -90 | -285 | 38 |
| Net cash used in financing activities | 711 | 49,556 | 8,797 | 216,236 |
| Net decrease in cash, cash equivalents and restricted cash | -43,191 | 22,587 | -15,417 | 173,725 |
| Cash, cash equivalents and restricted cash at the beginning of the period | 322,531 | 299,944 | 141,636 | - |
| Cash, cash equivalents and restricted cash at the end of the period | 279,340 | 322,531 | 299,944 | - |
Taysha Gene Therapies, Inc. (TSHA)
Taysha Gene Therapies, Inc. (TSHA)